Why is flecainide not commonly used for rhythm control?

Why Flecainide Is Not Commonly Used for Rhythm Control

Flecainide's limited use stems primarily from the landmark Cardiac Arrhythmia Suppression Trial (CAST), which demonstrated increased mortality in post-myocardial infarction patients, creating a broad contraindication that extends to all patients with structural heart disease—a restriction that excludes the majority of patients with atrial fibrillation who are typically older with comorbidities. 1

The CAST Trial Legacy

The CAST trial fundamentally changed flecainide prescribing patterns. In this study, patients with prior myocardial infarction and ventricular ectopy treated with flecainide had:

• Increased total mortality (5.1% vs 2.3% placebo)
• Increased risk of cardiac arrest and arrhythmic death
• The mechanism was monomorphic ventricular tachycardia, not torsades de pointes 1

This single trial created a safety paradigm that has persisted for over three decades, despite studying only a narrow population (post-MI patients with ventricular ectopy and reduced ejection fraction). 2

Current Contraindications That Limit Use

Flecainide is contraindicated in patients with: 1, 3, 1, 3, 2

Absolute Contraindications:

• Coronary artery disease (any form)
• Heart failure with reduced ejection fraction (NYHA class II-IV or LVEF <30%)
• Structural heart disease including:
  • Left ventricular dysfunction
  • Ventricular scar tissue
  • Severe left ventricular hypertrophy
• Ventricular conduction delays (QRS >120 ms)
• Recent myocardial infarction
• Chronic atrial fibrillation (not adequately studied) 2

Additional Safety Concerns:

• Potent negative inotropic effects that can worsen heart failure 1
• Risk of 1:1 atrioventricular conduction during atrial flutter, causing paradoxical ventricular rate acceleration 2
• Hypotension with intravenous formulation 1

The Clinical Reality: Most AF Patients Are Excluded

The practical limitation is that most patients with atrial fibrillation have some form of structural heart disease—whether coronary disease, hypertension with LVH, or heart failure. This makes the eligible population for flecainide quite small. 3

Flecainide can only be safely used in patients WITHOUT significant structural heart disease. 3, 4 This restriction is explicitly stated in current guidelines and FDA labeling. 2

When Flecainide IS Appropriate

Despite these limitations, flecainide remains highly effective when used in the right population:

Approved indications in patients WITHOUT structural heart disease: 3, 4, 2

• Paroxysmal supraventricular tachycardias (PSVT)
• Paroxysmal atrial fibrillation with disabling symptoms
• Pharmacological cardioversion of recent-onset AF
• Maintenance of sinus rhythm after cardioversion
• "Pill-in-the-pocket" approach for acute episodes

Efficacy data shows: 3

• Approximately doubles the likelihood of maintaining sinus rhythm
• Number needed to treat = 4 patients for 1 year
• More effective than sotalol but less effective than amiodarone

Monitoring Requirements Further Limit Use

Even in eligible patients, flecainide requires careful monitoring: 3

• Regular ECG monitoring at initiation and dose changes
• QRS duration must be monitored—increase >25% from baseline signals proarrhythmic risk requiring dose reduction or discontinuation
• Concomitant AV nodal blockade (beta-blocker or calcium channel blocker) is recommended to prevent rapid ventricular response if atrial flutter develops
• Precautions with intraventricular conduction delay, particularly left bundle branch block

Comparison to Amiodarone

Amiodarone has largely supplanted flecainide because: 3

• Can be safely used in patients WITH structural heart disease including heart failure
• Superior efficacy for maintaining sinus rhythm (NNT = 3 vs 4 for flecainide)
• Lower risk of torsades de pointes despite QT prolongation
• No restriction based on cardiac structure

The trade-off is amiodarone's significant extracardiac toxicity (pulmonary, hepatic, thyroid, neurologic, cutaneous, ocular), but this is often considered acceptable given the broader eligible population. 1

Emerging Reconsideration

Recent observational data suggests the CAST findings may not apply universally to all structural heart disease populations, particularly: 5, 6, 7

• Stable coronary disease without active ischemia
• Preserved left ventricular function
• Selected cardiomyopathies

However, current guidelines have not changed, and prospective randomized trials are needed before expanding use. 5, 7

Common Pitfalls to Avoid

1. Do not use flecainide in chronic atrial fibrillation—only paroxysmal AF is indicated 2
2. Always screen for structural heart disease before initiating—this requires echocardiography and assessment for coronary disease
3. Never use as monotherapy without rate-controlling agents (beta-blocker or calcium channel blocker) due to risk of 1:1 flutter conduction 3
4. Avoid in renal dysfunction without dose adjustment
5. Check baseline QRS duration—if >120 ms, flecainide is contraindicated 1

The Bottom Line

Flecainide is not commonly used because the majority of patients requiring rhythm control have structural heart disease that contraindicates its use. While highly effective in the minority of patients with "lone" atrial fibrillation or PSVT without cardiac abnormalities, the CAST trial created a mortality signal that appropriately restricts its use to a carefully selected, structurally normal population—a demographic that represents only a small fraction of the overall AF population requiring rhythm control.